Dear Editor, Type 1 diabetes mellitus (T1D) is an autoimmune disease characterized by the infiltration of inflammatory cells into the pancreatic islets of Langerhans, followed by the selective destruction of insulin-producing β-cells, resulting in hyperglycemia. One of the mechanisms causing β-cell death is the intra-islet release of inflammatory mediators such as interleukin-1β (IL-1β), tumor necrosis factor (TNF) and interferon-γ (IFN-γ) by activated immune cells. 1 Hence, the transcription factor NF-κB promotes pro-inflammatory and pro-apoptotic responses in β-cells on cytokine exposure. A transgenic mouse line in which NF-κB activation is attenuated specifically in β-cells conferred nearly complete protection against multiple low dose streptozotocin (MLDSTZ)-induced T1D. 2 Contrary, mice with constitutively active NF-κB signaling in β-cells spontaneously develop full-blown immune-mediated diabetes. 3 The ubiquitin-editing enzyme A20 is a critical negative regulator of NF-κB signaling in response to multiple stimuli, including TNF and IL-1. Moreover, A20 can also act as a strong anti-apoptotic protein in specific cell types.
4 A20 has been identified as the most highly upregulated anti-apoptotic protein in cytokine-stimulated primary islets and insulinoma cell lines. 5 Consistent with this, overexpression of A20 in islets confers resistance to cytokine-mediated activation of NF-κB, protecting them from apoptosis in the early posttransplantation period. 6 Interestingly, not only have NF-κB polymorphisms been identified in patients with T1D, 7 also A20/TNFAIP3 has been identified as a T1D susceptibility locus in humans. 8 Together, these data suggest an important role for A20 in β-cell function and T1D. Therefore, we generated and characterized A20-deficient mice which lack expression of A20 specifically in β-cells (Supplementary Figure 1A) .
We first confirmed the anti-apoptotic function of A20 in β-cells, as primary islets isolated from β-cell-specific A20 knockout (A20 β − KO ) mice were more susceptible to cytokine-induced cell death compared with wild-type islets (Supplementary Figure 1A) . As A20 has a crucial role in β-cell survival in vitro, we next investigated whether A20 β-KO mice would be more susceptible to diabetes development when compared with wild-type littermates. A20
β-KO mice aged normally without any evidence of metabolic defects. Phenotypic analysis of A20 β-KO mice up to the age of 12 months revealed no pathological signs in the pancreas. A20
β-KO mice and control littermates were subjected to a model of T1D induced by MLDSTZ, however, both control and A20 β-KO mice developed a similar hyperglycemia, which was confirmed in a glucose tolerance test (ipGTT) performed 5 weeks after the first STZ injection (Supplementary Figure 1B) . Next, we crossed A20 β-KO mice with C57BL6-Ins2 Akita /J mice, which carry a mutation in the insulin Ins2 gene that prevents normal folding and secretion and induces endoplasmic reticulum stress leading to β-cell death. Mice carrying the Ins2 Akita mutation become hyperglycemic very early in life, however, no differences could be observed in conditions of A20 deficiency in β cells. In agreement, ipGTT shows severe and similar defects in insulin secretion in both Ins2
Akita and A20
β − KO/Akita mice (Supplementary Figure 1C) . Finally, A20 β-KO mice were backcrossed into a non-obese diabetic genetic background, and glucose levels were measured every week in order to follow diabetes development. Although only 40% of all mice developed diabetes, no differences could be detected between control and A20 β-KO mice (Supplementary Figure 1D) . In conclusion, A20 deficiency in β cells does not affect β-cell apoptosis nor disease development in vivo.
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